161 related articles for article (PubMed ID: 7908972)
1. Dopamine antagonists can inhibit methamphetamine sensitization, but not cocaine sensitization, when assessed by ambulatory activity in mice.
Kuribara H; Uchihashi Y
J Pharm Pharmacol; 1993 Dec; 45(12):1042-5. PubMed ID: 7908972
[TBL] [Abstract][Full Text] [Related]
2. Modification of cocaine sensitization by dopamine D1 and D2 receptor antagonists in terms of ambulation in mice.
Kuribara H
Pharmacol Biochem Behav; 1995 Aug; 51(4):799-805. PubMed ID: 7675862
[TBL] [Abstract][Full Text] [Related]
3. Effects of dopamine antagonism on methamphetamine sensitization: evaluation by ambulatory activity in mice.
Kuribara H; Uchihashi Y
Pharmacol Biochem Behav; 1994 Jan; 47(1):101-6. PubMed ID: 8115410
[TBL] [Abstract][Full Text] [Related]
4. Can posttreatment with the selective dopamine D2 antagonist, YM-09151-2, inhibit induction of methamphetamine sensitization? Evaluation by ambulatory activity in mice.
Kuribara H
Pharmacol Biochem Behav; 1994 Oct; 49(2):323-6. PubMed ID: 7824544
[TBL] [Abstract][Full Text] [Related]
5. Modification of morphine sensitization by opioid and dopamine receptor antagonists: evaluation by studying ambulation in mice.
Kuribara H
Eur J Pharmacol; 1995 Mar; 275(3):251-8. PubMed ID: 7768292
[TBL] [Abstract][Full Text] [Related]
6. Selective antagonism of dopamine D1 and D2 receptors does not block the development of behavioral sensitization to cocaine.
Mattingly BA; Hart TC; Lim K; Perkins C
Psychopharmacology (Berl); 1994 Mar; 114(2):239-42. PubMed ID: 7838914
[TBL] [Abstract][Full Text] [Related]
7. Co-administration of either a selective D1 or D2 dopamine antagonist with methamphetamine prevents methamphetamine-induced behavioral sensitization and neurochemical change, studied by in vivo intracerebral dialysis.
Hamamura T; Akiyama K; Akimoto K; Kashihara K; Okumura K; Ujike H; Otsuki S
Brain Res; 1991 Apr; 546(1):40-6. PubMed ID: 1677305
[TBL] [Abstract][Full Text] [Related]
8. Role of dopamine D1 receptors in the lethal effects of cocaine and a quaternary methiodide analog.
Witkin JM; Newman AH; Nowak G; Katz JL
J Pharmacol Exp Ther; 1993 Oct; 267(1):266-74. PubMed ID: 7901394
[TBL] [Abstract][Full Text] [Related]
9. SK&F 83822 distinguishes adenylyl cyclase from phospholipase C-coupled dopamine D1-like receptors: behavioural topography.
O'Sullivan GJ; Roth BL; Kinsella A; Waddington JL
Eur J Pharmacol; 2004 Feb; 486(3):273-80. PubMed ID: 14985049
[TBL] [Abstract][Full Text] [Related]
10. Effects of D2 or combined D1/D2 receptor antagonism on the methamphetamine-induced one-trial and multi-trial behavioral sensitization of preweanling rats.
Mohd-Yusof A; Veliz A; Rudberg KN; Stone MJ; Gonzalez AE; McDougall SA
Psychopharmacology (Berl); 2016 Mar; 233(5):893-903. PubMed ID: 26650612
[TBL] [Abstract][Full Text] [Related]
11. SCH 23390 equivalently, but YM-09151-2 differentially reduces the stimulant effects of methamphetamine, MK-801 and ketamine: assessment by discrete shuttle avoidance in mice.
Kuribara H; Uchihashi Y
Jpn J Pharmacol; 1993 May; 62(1):111-4. PubMed ID: 8101884
[TBL] [Abstract][Full Text] [Related]
12. Dopamine D1 receptor antagonist SCH 23390 retards methamphetamine sensitization in both combined administration and early posttreatment schedules in mice.
Kuribara H
Pharmacol Biochem Behav; 1995 Dec; 52(4):759-63. PubMed ID: 8587917
[TBL] [Abstract][Full Text] [Related]
13. Administration of SCH 23390 into the medial prefrontal cortex blocks the expression of MDMA-induced behavioral sensitization in rats: an effect mediated by 5-HT2C receptor stimulation and not by D1 receptor blockade.
Ramos M; Goñi-Allo B; Aguirre N
Neuropsychopharmacology; 2005 Dec; 30(12):2180-91. PubMed ID: 15841107
[TBL] [Abstract][Full Text] [Related]
14. Expression of behavioral sensitization to the cocaine-like fungicide triadimefon is blocked by pretreatment with AMPA, NMDA and DA D1 receptor antagonists.
Reeves R; Thiruchelvam M; Cory-Slechta DA
Brain Res; 2004 May; 1008(2):155-67. PubMed ID: 15145752
[TBL] [Abstract][Full Text] [Related]
15. Effects of YM-09151-2, a potent and selective dopamine D2 antagonist, on the ambulation-increasing effect of methamphetamine in mice.
Kuribara H; Tadokoro S
Jpn J Pharmacol; 1990 Mar; 52(3):489-92. PubMed ID: 1970609
[TBL] [Abstract][Full Text] [Related]
16. Dopamine receptor antagonists prevent expression, but not development, of morphine sensitization.
Jeziorski M; White FJ
Eur J Pharmacol; 1995 Mar; 275(3):235-44. PubMed ID: 7768290
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of methamphetamine sensitization by post-methamphetamine treatment with SCH 23390 or haloperidol.
Kuribara H
Psychopharmacology (Berl); 1995 May; 119(1):34-8. PubMed ID: 7675947
[TBL] [Abstract][Full Text] [Related]
18. Dopamine receptor antagonists fail to prevent induction of cocaine sensitization.
White FJ; Joshi A; Koeltzow TE; Hu XT
Neuropsychopharmacology; 1998 Jan; 18(1):26-40. PubMed ID: 9408916
[TBL] [Abstract][Full Text] [Related]
19. Localization of dopamine receptor subtypes occupied by intra-accumbens antagonists that reverse cocaine-induced locomotion.
Neisewander JL; O'Dell LE; Redmond JC
Brain Res; 1995 Feb; 671(2):201-12. PubMed ID: 7743209
[TBL] [Abstract][Full Text] [Related]
20. Development of behavioral sensitization to the cocaine-like fungicide triadimefon is prevented by AMPA, NMDa, DA D1 but not DA D2 receptor antagonists.
Reeves R; Thiruchelvam M; Cory-Slechta DA
Toxicol Sci; 2004 May; 79(1):123-36. PubMed ID: 15014204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
